The estimated Net Worth of Jeffrey W. Albers is at least 37.4 百万$ dollars as of 9 September 2024. Mr. Albers owns over 19,702 units of Blueprint Medicines Corp stock worth over 13,638,134$ and over the last 9 years he sold BPMC stock worth over 14,417,344$. In addition, he makes 9,362,370$ as Chief Executive Officer、 Director at Blueprint Medicines Corp.
Jeffrey has made over 56 trades of the Blueprint Medicines Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 19,702 units of BPMC stock worth 1,685,900$ on 9 September 2024.
The largest trade he's ever made was exercising 40,000 units of Blueprint Medicines Corp stock on 23 March 2020 worth over 212,800$. On average, Jeffrey trades about 12,652 units every 43 days since 2015. As of 9 September 2024 he still owns at least 157,557 units of Blueprint Medicines Corp stock.
You can see the complete history of Mr. Albers stock trades at the bottom of the page.
Jeffrey W. Albers J.D. serves as Chief Executive Officer, Director of the Company. Mr. Albers has served as our president and chief executive officer and a member of our board of directors since July 2014. In addition, Mr. Albers currently serves on the board of directors, audit committee and compensation committee of Magenta Therapeutics, Inc. and on the board of directors of the New England Division of the American Cancer Society. Mr. Albers has nearly a decade of experience in leadership roles in the biopharmaceutical industry. Prior to joining us, from January 2012 to April 2014, he was president of Algeta ASA, or Algeta, a Norwegian biopharmaceutical company, where he oversaw the commercial and business functions. At Algeta, Mr. Albers was responsible for the U.S. launch of Radium-223 in metastatic castrate resistant prostate cancer. Prior to Algeta, from July 2005 to November 2011, Mr. Albers was at Genzyme Corporation, or Genzyme, a biotechnology company that is now a wholly-owned subsidiary of Sanofi S.A., most recently as vice president of the U.S. hematology and oncology business unit. Mr. Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University.
As the Chief Executive Officer、 Director of Blueprint Medicines Corp, the total compensation of Jeffrey Albers at Blueprint Medicines Corp is 9,362,370$. There are no executives at Blueprint Medicines Corp getting paid more.
Jeffrey Albers is 48, he's been the Chief Executive Officer、 Director of Blueprint Medicines Corp since 2020. There are 22 older and 5 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over 126,865,732$ worth of Blueprint Medicines Corp stock and bought 131,110 units worth 2,599,105$ . The most active insiders traders include Llc Fmr、Kevin P Starr、Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of 1,362,195$. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth 1,685,900$.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: